{"title":"慢性淋巴细胞白血病:新的联合疗法和新药物的发展是一个惊人的时代,但仍然没有治愈,需要关注患者特异性治疗方案","authors":"Nicole Lamanna MD","doi":"10.3816/CLK.2008.n.028","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"2 4","pages":"Pages 221-222"},"PeriodicalIF":0.0000,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2008.n.028","citationCount":"0","resultStr":"{\"title\":\"Chronic Lymphocytic Leukemia: An Amazing Time Given the Development of New Combination Therapies and New Agents, but Still No Cure, and a Need to Focus on Patient-Specific Treatment Options\",\"authors\":\"Nicole Lamanna MD\",\"doi\":\"10.3816/CLK.2008.n.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":100271,\"journal\":{\"name\":\"Clinical Leukemia\",\"volume\":\"2 4\",\"pages\":\"Pages 221-222\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3816/CLK.2008.n.028\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1931692513600340\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931692513600340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chronic Lymphocytic Leukemia: An Amazing Time Given the Development of New Combination Therapies and New Agents, but Still No Cure, and a Need to Focus on Patient-Specific Treatment Options